AM-Pharma flies white flag on PhIII battle, but they aren't giving up on their kidney drug
The Dutch biotech AM-Pharma lost the Phase III battle on kidney disease, but they’re still fighting the long regulatory war.
The biotech put out word early Thursday that the team has shuttered their Phase III trial for ilofotase alfa that guards against kidney injury after the treatment failed an interim analysis on the primary: 28-day all cause mortality.
But they went on to analyze all the data from patients suffering from sepsis-associated acute kidney injury and researchers claimed a significant response on a key secondary for a reduction on Major Adverse Kidney Events by day 90 (MAKE90). Making that case may not be so easy, though.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
